ATR
ATR is a DNA-damage alarm kinase. Blocking it makes tumours with broken repair systems collapse under their own replication stress.
ATR inhibitors (ceralasertib, camonsertib, elimusertib) are in phase 2/3, notably ceralasertib with durvalumab in NSCLC after immunotherapy (LATIFY) and in ATM-deficient tumours. No approval yet; toxicity (myelosuppression) limits combinations.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ATR is a DNA-damage alarm kinase. Blocking it makes tumours with broken repair systems collapse under their own replication stress.
- 1 · What it is
ATR is a DNA-damage alarm kinase. Blocking it makes tumours with broken repair systems collapse under their own replication stress.
- 2 · What goes wrong in cancer
PI3K-like kinase activated by single-stranded DNA at stalled forks; signals via CHK1.
- 3 · How drugs use it
No product in this corpus aims at ATR yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Biology
PI3K-like kinase activated by single-stranded DNA at stalled forks; signals via CHK1.
- Tumours with ATM loss, replication stress, or PARP-inhibitor resistance
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 5-10% | ATM loss/mutation (sensitising context) | cBioPortal (TCGA) | |
| Ovarian cancer | n/a | Replication-stress context; no expression threshold | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"ATR" OR ABSTRACT:"ATR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATR, not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetWEE1
Shares The p53 network (guardian of the genome), DNA replication stress, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies and the tag ddr.
- TechnologyHRD & BRCA testing
Shares Enabling characteristic: genome instability and mutation, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.
- TargetPARP
Shares Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed), Radioligand plus DNA-repair inhibitor combinations, Enabling characteristic: genome instability and mutation, Base excision repair, PARP & alkylation damage.
- TechnologyPARP PET
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, Ovarian cancer, Triple-negative breast cancer (TNBC).
- ProductTalazoparib
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.
- ProductNiraparib
Shares Base excision repair, PARP & alkylation damage, DNA damage response & homologous recombination, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.
- PathwayThe cell-cycle engine (cyclins & CDKs)
Shares DNA replication & origin licensing, DNA replication stress, p53 / RB / cell-cycle checkpoint, Small-cell lung cancer.
- TermSynthetic lethality
Shares Base excision repair, PARP & alkylation damage, DNA replication stress, Synthetic lethality: paired dependencies, Double-strand break repair: HR versus end joining.